stockrow
Saturday 7 November 2026
Export FULC’s income statement to Excel — free account
Fulcrum Therapeutics, Inc.
FULC Healthcare Biotechnology
Fulcrum Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $80.0 million, up 2,752.0% from fiscal 2023.
- EPS
- −21.4%
- Free cash flow
- −13.1%
Quarter to June 2026, against a year earlier
3.71
0.03
+0.82%
Follow FULC
Alert me
Fulcrum Therapeutics, Inc. (FULC) P/E ratio
Fulcrum Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| 13 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TTRX Turn Therapeutics Inc. compare | n/m |
| KYTX Kyverna Therapeutics, Inc. compare | n/m |
| FULC Fulcrum Therapeutics, Inc. | n/m |
| PRLD Prelude Therapeutics Incorporated compare | n/m |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| DTIL Precision BioSciences, Inc. compare | n/m |
| OCGN Ocugen, Inc. compare | n/m |
| IPSC Century Therapeutics, Inc. compare | n/m |
| AGEN Agenus Inc. compare | 10.7× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)